SCHEMBL5872145

SCHEMBL5872145

Cc1ccc2c([O-])c([I+]c3ccccc3)c(=O)n(Cc3ccccc3)c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.41
LMNA P02545 3/20 0.41
RECQL P46063 2/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ADORA1 P30542 1/20 0.40
HPGD P15428 3/20 0.40
KDM4E B2RXH2 3/20 0.40
HTT P42858 2/20 0.40
GAA P10253 2/20 0.40
TSHR P16473 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
PSMD14 O00487 1/20 0.40
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7959767 0.86 KMT2A (0.41) ALDH1A1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL5871960 0.82 CNR1 (0.45) MEN1KMT2AMAPTPTGDR2PDE4A
SCHEMBL7953032 0.74 ADORA1 (0.41) ALDH1A1LMNARECQLRAB9ASMN1; SMN2
SCHEMBL5872307 0.71 CCNA2 (0.39) ALDH1A1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL7945856 0.71 HDAC1 (0.48) ALDH1A1LMNARAB9ASMN1; SMN2MEN1
SCHEMBL11488105 0.70 CNR1 (0.47) ALDH1A1LMNARECQLRAB9ASMN1; SMN2
SCHEMBL5872030 0.70 PDE4D (0.43) ALDH1A1LMNASMN1; SMN2MEN1KMT2A
SCHEMBL1522428 0.69 ADORA1 (0.46) ALDH1A1LMNARECQLRAB9ASMN1; SMN2
SCHEMBL5871423 0.68 KDM4E (0.58) ALDH1A1LMNARECQLRAB9ASMN1; SMN2
SCHEMBL5871920 0.67 FEN1 (0.45) ALDH1A1KDM4EHTTTSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071187-B2 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2006-07-04 US disclosed
US-20040214853-A1 Naphthyridine derivatives OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-10-28 US disclosed
EP-1426374-A1 NAPHTHYRIDINE DERIVATIVE OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2004-06-09 EP disclosed
US-6245779-B1 ANALGESICS; ANTIINFLAMMATORY AGENTS OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2001-06-12 US disclosed
EP-0997463-A1 NAPHTHYRIDINE DERIVATIVES OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 2000-05-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040214853-A1 Naphthyridine derivatives MT-ND1, OPRD1, NR0B1 ALDH1A1 272/4885LMNA 2666/4885RECQL 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.